Clinical trials: Chronic Obstr Lung Disease
Chronic Obstructive Pulmonary Disease
A Study to Assess the Long-term Safety of QVA149
The study is designed to provide long-term safety data for QVA149 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- ENLIGHTEN (NCT01120717)
- Testing
- QVA149
- Where
- 53 sites in Canada, France and 8 more
- Volunteers
- 339 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease, COPD Exacerbation
Testing a Prediction Algorithm Into a Running Telehealth System for Patients With COPD
This trial will test a COPD prediction algorithm into a telehealth system from the previous Danish large-scale trial, TeleCare North (NCT01984840).
- Conditions
- Chronic Obstructive Pulmonary Disease, COPD Exacerbation, COPD Exacerbation Acute, COPD
- Trial name
- NCT05218525
- Testing
- Algorithm
- Where
- Denmark
- Volunteers
- 138 people
- Sponsor
- Aalborg University
Chronic Obstructive Pulmonary Disease, Asthma
Impact of Air Pollution on Chronic Respiratory Diseases
The aim of this study is to evaluate the impact of air pollution on the occurrence and clinical course of chronic respiratory diseases, and discover new biomarkers from various devices such as CT images that can indicate the…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT03813810
- Testing
- Non
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease
Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice
- Trial name
- NCT02236715
- Testing
- Atrovent®
- Volunteers
- 1,039 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease, Hypoxia
Effect of Oxygen Supplementation During Exercise in Chronic Obstructive Pulmonary Disease Patients
The project will test the hypothesis that lung ventilation during exercise is unaffected by oxygen supplementation. In addition, the acute effect of oxygen supplementation on dyspnoea, heart rate and blood pressure will be…
- Trial name
- NCT02108925
- Testing
- Oxygen
- Where
- Norway
- Volunteers
- 16 people
- Sponsor
- LHL Helse
Chronic Obstructive Pulmonary Disease (COPD)
A Trial to Evaluate the Safety and Efficacy of HL231 Solution for Inhalation in Patients with COPD
To evaluate the efficacy and safety of HL231 Solution for Inhalation vs Ultibro in Chinese patients with moderate to severe COPD.
- Trial name
- NCT06619210
- Testing
- HL231 Dose 1/2/3/4
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Chronic Obstructive Pulmonary Disease
A Study to Show That Flutiform is Well Tolerated and Effective in the Treatment of COPD
Efficacy of Fluticasone/Formoterol in COPD Treatment. The Effect study.
- Trial name
- NCT01946620
- Testing
- Flutiform, Formoterol
- Where
- 15 sites in Bulgaria, Germany and 13 more
- Volunteers
- 1,767 people
- Sponsor
- Mundipharma Research Limited
Chronic Obstructive Pulmonary Disease (COPD)
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
Patients with COPD (chronic bronchitis and/or emphysema) are known to be at an increased risk of heart disease and death due to heart attacks.
- Trial name
- NCT03487406
- Testing
- Ticagrelor, Aspirin
- Where
- United Kingdom
- Volunteers
- 120 people
- Sponsor
- Newcastle-upon-Tyne Hospitals NHS Trust
Pulmonary Disease, Chronic Obstructive
Staphylococcus and Neisseria Tablets in the Treatment of Acute Exacerbations of Chronic Obstructive Pulmonary Disease.
It is planned to enroll 495 acute exacerbation of chronic obstructive pulmonary disease patients, and they will be randomly assigned to the high-dose test group, normal dose test group or control group at a ratio of 1:1:1, with…
- Trial name
- NCT05543343
- Testing
- High dose or normal dose staphylococcus albicans
- Where
- China
- Volunteers
- 495 people
- Sponsor
- Qu Yiqing
Chronic Obstructive Pulmonary Disease
IN UTERO SMOKING AND PREMATURE CELLULAR SENESCENCE
Actually, there is an increasing number of arguments for a premature origin of chronic adult's diseases, as the chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT01865435
- Testing
- cord blood sample
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
COPD
Assessing Exercise Capacity After PulseHaler™ Treatment in GOLD II-IV COPD Patients
Prospective, sham controlled, interventional study to evaluate the extent to which PulseHaler improves the functional status of Chronic Obstructive Lung Disease (GOLD) II-IV Chronic obstructive pulmonary disease (COPD) patients.
- Trial name
- NCT04236076
- Testing
- PulseHaler
- Volunteers
- 104 people
- Sponsor
- Respinova LTD
Chronic Obstructive Pulmonary Disease
Alveolar-capillary Reserve After Exercise in Chronic Obstructive Pulmonary Disease (COPD) (COP-DTPA)
It is unknown whether individuals with COPD exhibit abnormal alveolar-capillary breaching during exercise, and whether this contributes to exertional dyspnoea.
- Trial name
- NCT06287476
- Testing
- Acute exercise bout on visit 2 and 3
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
COPD
QualiTy of Life Evaluation in Patients With ChRonic ObstructIve Pulmonary Disease Who Require Tiotropium as additiOnal treatmeNt.
Chronic obstructive pulmonary disease (COPD) is a complex, heterogeneous disease usually with a decline lung function and worsening symptoms; hence, both forced expiratory volume in 1 s (FEV1; lung function) and validated…
- Trial name
- TRITON (NCT06170125)
- Testing
- Tiotropium treated patients
- Volunteers
- 500 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Chronic Obstructive Pulmonary Disease (COPD)
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to…
- Trial name
- NCT03573817
- Testing
- Revefenacin, Formoterol
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Mylan Inc.
Pulmonary Disease, Chronic Obstructive
Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)
The primary objectives of this study are to assess bronchodilator efficacy as determined by forced expiratory volume in one second (FEV1), the effect on dyspnoea as determined by the Baseline Dyspnoea Index/Transition Dyspnoea…
- Trial name
- NCT00662740
- Testing
- FDC tiotropium / salmeterol, Salmeterol, Tiotropium (Spiriva®)
- Where
- 72 sites in United States, Austria and 16 more
- Volunteers
- 220 people
- Sponsor
- Boehringer Ingelheim
COPD Exacerbation
Evaluation of the Efficacy of Different Nebulization Techniques
COPD is the 3rd most common cause of death in the world, and the most common places of admission in our country with exacerbation of COPD are emergency services.
- Trial name
- NCT05507060
- Testing
- Vibrating MESH nebulizer (Aerogen Ultra), Jet nebulizers (Philips Respironics)
- Where
- Turkey (Türkiye)
- Volunteers
- 96 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
Cardiovascular Diseases, Coronary Disease
Honolulu Heart Program
To investigate coronary heart disease and stroke among American men of Japanese ancestry who were living on the island of Oahu in 1965. Morbidity and mortality surveillance of the original cohort is continuing.
- Conditions
- Cardiovascular Diseases, Coronary Disease, Cerebrovascular Accident, Heart Diseases
- Trial name
- NCT00005123
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
COPD
A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator
This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world.
- Trial name
- NCT01794780
- Testing
- LABA based treatment: indacaterol, LAMA based treatment: tiotropium, LABA/ICS based treatment: salmeterol/fluticasone
- Where
- 2 sites in China
- Volunteers
- 2,229 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
The primary objective of this study is to compare the bronchodilator efficacy of three doses (50 µg, 100 µg and 200 µg) of BEA 2180 delivered by the Respimat® once daily to placebo and tiotropium bromide delivered by the…
- Trial name
- NCT00528996
- Testing
- BEA 2180 BR, Tiotropium Bromide
- Where
- 178 sites in United States, Canada and 8 more
- Volunteers
- 2,080 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease Severe, Interstitial Lung Disease
Effect of HIgh-flow Therapy in Long-term Oxygen Therapy
This is a registry-based, randomized, controlled clinical trial of the effect of added high-flow oxygen therapy (using the device Lumis HFT) during one year in people with long-term oxygen therapy (LTOT) for chronic obstructive…
- Conditions
- Chronic Obstructive Pulmonary Disease Severe, Interstitial Lung Disease, Chronic Respiratory Failure With Hypoxia
- Trial name
- HILOT (NCT06247397)
- Testing
- Added high-flow oxygen therapy, Standard care
- Where
- 2 sites in Sweden
- Volunteers
- 310 people
- Sponsor
- Skane University Hospital